Part 8. Preparations, Mixtures and Natural Products

Recommendation	Reference (source)
The Board again recommends that **pharmaceutical preparations containing scheduled substances be controlled in the same way as the substances themselves**.	(PRE/2008/P93) (PRE/2007/P43) (PRE/2007/P86) (AR/2007/R17) (PRE/2006/P134) (PRE/2005/P135) (AR/2005/R13)
Since 2003, the Board has recommended that **international trade in pharmaceutical preparations should be monitored in the same manner as the precursors that those preparations contain**. Maintaining seamless and effective **regulatory controls** over both precursor chemicals and pharmaceutical preparations containing those chemicals **requires close cooperation between different competent authorities**.	(PRE/2012/P145)
Concerned about the continuing diversion of **pharmaceutical preparations** containing internationally controlled substances, the Board reiterates its **request to UNODC to assist the Governments concerned in monitoring trends and preventing the diversion and abuse** of such preparations.	(AR/2006/R33)
The Board has endorsed the conclusions of its advisory expert group convened during June 1996 that the control measures over substances listed in the tables of the 1988 Convention should be also directly applicable to the following types of **mixtures**: (a) Combinations where additional (unscheduled) ingredients are present solely as additives such as preservatives, anti-oxidants or stabilizers; (b) Simple solutions of scheduled substances in the form of solutions; (c) Combinations knowingly formulated to circumvent existing controls.	(PRE/2004/P45)
INCB reminds Governments to consider, to the extent possible and in accordance with national legislation, **applying control measures for pharmaceutical preparations containing ephedrine or pseudoephedrine similar to those for the bulk** (raw) substances.	(PRE/2016/P72)
The Board urges all Governments to **control pharmaceutical preparations** containing ephedrine and pseudoephedrine **in the same way as they control the scheduled substances themselves**, ensuring, at the same time, that **legitimate trade is not unduly impeded** in the process.	(AR/2008/R31) (AR/2010/R30) (PRE/2009/P52) (PRE/2009/P104) (AR/2009/R35) (PRE/2008/P46) (AR/2007/R17)
The Board therefore requests that Governments, in their efforts to scrutinize shipments of preparations containing **ephedrine and pseudoephedrine**, give due regard to the content of such **preparations**.	(PRE/2010/P87)
All exporting and transit countries are urged not to release shipments of ephedrine or pseudoephedrine until the **legitimacy of those shipments has been duly confirmed**. Governments are urged to ensure that **mechanisms are in place for verifying** not only the legitimacy of the raw material when imported but also the **intended end-use** of the material, especially in the case of pharmaceutical preparations intended for export to another country.	(PRE/2008/P46)
The Board **welcomes the increased focus on shipments** of **ephedrine** and **pseudoephedrine in the form of**	(AR/2011/R18) (PRE/2011/P20)

pharmaceutical preparations and encourages Governments to implement the measures outlined in **Commission on Narcotic Drugs resolution 54/8**.	(PRE/2011/P159)
The Board again encourages exporting countries to **provide pre-export notifications** for all requested **exports of ephedrine and pseudoephedrine preparations**.	(PRE/2007/P86) (PRE/2006/P134) (AR/2005/R13)
The Board welcomes the increased focus on shipments of **ephedrine** and **pseudoephedrine** in the form of **preparations** and encourages Governments to also **pay attention to the ephedrine or pseudoephedrine content in these preparations**. This can vary significantly; in past years, **ephedrine** or **pseudoephedrine** content of between 30 mg and 300 mg in tablets has been notified to the Board.	(PRE/2010/P36)
The Board urges all Governments in the **Americas** to continue monitoring the licit trade in **precursors of amphetamine-type stimulants**, including **ephedrine** and **pseudoephedrine** traded in the form of pharmaceutical preparations.	(PRE/2008/P50)
The Board encourages exporting countries to **send pre-export notifications for shipments of pharmaceutical preparations to the Americas**.	(PRE/2006/P81)
All exporting and transit countries are **urged not to release shipments** of **ephedrine** and **pseudoephedrine** destined to **Africa**, the **Americas** and **West Asia until the legitimacy of those shipments has been duly confirmed**. Governments are urged to ensure that mechanisms are in place for **verifying** not only the legitimacy of the raw material when imported, but also the **intended end-use of the material**, especially in the case of pharmaceutical preparations intended for export to another country.	(PRE/2007/P43) (PRE/2007/P85) (PRE/2006/P134)
The Board urges the competent authorities of **Pakistan** to launch investigations into the export of **pharmaceutical preparations** from their country to ensure that similar diversions (a shipment that had originally been shipped from **Pakistan** to the **United Kingdom**, where it was repacked and exported to **Guinea**) to other countries have not taken place.	(PRE/2003/P78)
The Board urges the Governments of importing countries in the region (**West Asia**), including within the framework of the Subcommission on Illicit Drug Traffic and Related Matters in the **Near and Middle East**, to take appropriate measures to **monitor the manufacture, distribution and export of preparations of ephedrine and pseudoephedrine**, in order to ensure that the end-users are legitimate and to prevent the accumulation of those substances in quantities exceeding their licit requirements.	(AR/2006/R23)
The Board strongly urges the Governments of countries in **West Asia** to pay close attention to **industrial products whose formulations contain P-2-P** to ensure that the substance cannot be readily extracted for the illicit manufacture of **amphetamine**. The Board recommends that such industrial products should be **monitored** in the same manner as are **pharmaceutical preparations** containing **ephedrine** or **pseudoephedrine**. Consideration should be given to identifying alternative chemicals to **P-2-P** for use in nonregulated industrial and household products.	(PRE/2008/P54)
The Board requests the Governments of all countries in **West Asia** to ensure that **adequate controls over P-2-P are**	(AR/2010/R32)

in place and to revise their annual requirements for that substance.	
The Board recommends that Governments **monitor all natural product sources** of **ephedrine alkaloids** in the same manner as is done with respect to **Ephedra sp**.	(PRE/2009/P79)